Understanding the Market | CARDIOFLOW-B rose over 4% in the morning and is expected to release its performance at the end of this month, with a projected net loss in the first half of the year decreasing by no less than 83% year-on-year
I'm PortAI, I can summarize articles.
CARDIOFLOW-B's stock price rose more than 4% in the morning, reaching HKD 1.54, with a transaction volume of HKD 16.2265 million. The company expects a net loss of no more than RMB 10 million in the first half of 2025, a year-on-year decrease of no less than 83%. The main reasons include the growth in overseas sales of the VitaFlow Liberty® product, the commercialization progress of the AnchorMan® system in China, resource allocation optimization, and gains from equity sales. The board of directors will hold a meeting on August 28 to review the interim performance
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments